Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma

Drljevic-Nielsen, Aska; Mains, Jill Rachel; Thorup, Kennet; Andersen, Michael Brun; Rasmussen, Finn; Donskov, Frede

doi:10.1007/s00330-022-08793-5

Cited by 8 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their second study continued the focus on CT parameters, corroborating the predictive value of iodine concentration and adding CT parameters, such as virtual monochromatic images at specific energy levels, as a predictive biomarker. These findings suggest that both pretreatment and spectral dual-layer CT parameters have prognostic utility and could potentially aid in risk stratification and treatment decision making in mRCC patients treated with different therapies [97,98].…”

Section: Ici Prospective Studiesmentioning

confidence: 86%

“…This study revealed that certain CT parameters, such as iodine concentration and virtual monochromatic images at specific energy levels, were significantly associated with progression-free survival and overall survival in mRCC patients receiving different therapies. These findings suggest that both pretreatment and spectral dual-layer CT parameters have prognostic utility and could potentially aid in risk stratification and treatment decision making in mRCC patients treated with different therapies [97,98].…”

Section: Vegf Tkis Prospective Studiesmentioning

confidence: 86%

See 1 more Smart Citation

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Dani,

Rich,

Kumar

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Challenges remain in determining the most effective treatment strategies and identifying patients who would benefit from adjuvant or neoadjuvant therapy in renal cell carcinoma. The objective of this review is to provide a comprehensive overview of biomarkers in metastatic renal cell carcinoma (mRCC) and their utility in prediction of treatment response, prognosis, and therapeutic monitoring in patients receiving systemic therapy for metastatic disease. Methods: A systematic literature search was conducted using the PubMed database for relevant studies published between January 2017 and December 2022. The search focused on biomarkers associated with mRCC and their relationship to immune checkpoint inhibitors, targeted therapy, and VEGF inhibitors in the adjuvant, neoadjuvant, and metastatic settings. Results: The review identified various biomarkers with predictive, prognostic, and therapeutic monitoring potential in mRCC. The review also discussed the challenges associated with anti-angiogenic and immune-checkpoint monotherapy trials and highlighted the need for personalized therapy based on molecular signatures. Conclusion: This comprehensive review provides valuable insights into the landscape of biomarkers in mRCC and their potential applications in prediction of treatment response, prognosis, and therapeutic monitoring. The findings underscore the importance of incorporating biomarker assessment into clinical practice to guide treatment decisions and improve patient outcomes in mRCC.

show abstract

Section: Ici Prospective Studiesmentioning

confidence: 86%

Section: Vegf Tkis Prospective Studiesmentioning

confidence: 86%

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Dani,

Rich,

Kumar

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Drljevic-Nielsen et al . [ 34 ] used the dual-energy CT IoD for early prediction of the efficacy of targeted therapy for metastatic renal cell carcinoma. IoD at baseline and after 1 month of chemotherapy were independent risk factors for outcomes in patients with mRCC.…”

Section: Discussionmentioning

confidence: 99%

Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab

Yuan

Yue

et al. 2023

Cancer Imaging

View full text Add to dashboard Cite

Purpose Early evaluation of the efficacy of first-line chemotherapy combined with bevacizumab in patients with colorectal cancer liver metastasis (CRLM) remains challenging. This study used 2-month post-chemotherapy spectral computed tomography (CT) to predict the overall survival (OS) and response of CRLM patients with bevacizumab-containing therapy. Method This retrospective analysis was performed in 104 patients with pathologically confirmed CRLM between April 2017 and October 2021. Patients were treated with 5-fluorouracil, leucovorin, oxaliplatin or irinotecan with bevacizumab. Portal venous phase spectral CT was performed on the target liver lesion within 2 months of commencing chemotherapy to demonstrate the iodine concentration (IoD) of the target liver lesion. The patients were classified as responders (R +) or non-responders (R −) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at 6 months. Multivariate analysis was performed to determine the relationships of the spectral CT parameters, tumor markers, morphology of target lesions with OS and response. The differences in portal venous phase spectral CT parameters between the R + and R − groups were analyzed. Receiver operating characteristic (ROC) curves were used to evaluate the predictive power of spectral CT parameters. Results Of the 104 patients (mean age ± standard deviation: 57.73 years ± 12.56; 60 men) evaluated, 28 (26.9%) were classified as R + . Cox multivariate analysis identified the iodine concentration (hazard ratio [HR]: 1.238; 95% confidence interval [95% CI]: 1.089–1.408; P < 0.001), baseline tumor longest diameter (BLD) (HR: 1.022; 95% CI: 1.005–1.038, P = 0.010), higher baseline CEA (HR: 1.670; 95% CI: 1.016–2.745, P = 0.043), K-RAS mutation (HR: 2.027; 95% CI: 1.192–3.449; P = 0.009), and metachronous liver metastasis (HR: 1.877; 95% CI: 1.179–2.988; P = 0.008) as independent risk factors for patient OS. Logistic multivariate analysis identified the IoD (Odds Ratio [OR]: 2.243; 95% CI: 1.405–4.098; P = 0.002) and clinical N stage of the primary tumor (OR: 4.998; 95% CI: 1.210–25.345; P = 0.035) as independent predictor of R + . Using IoD cutoff values of 4.75 (100ug/cm3) the area under the ROC curve was 0.916, sensitivity and specificity were 80.3% and 96.4%, respectively. Conclusions Spectral CT IoD can predict the OS and response of patients with CRLM after 2 months of treatment with bevacizumab-containing therapy.

show abstract

“…In the oncologic field, these parameters may play a pivotal role in tumor management, including diagnosis, characterization, grading, assessment of tumor invasiveness, staging, histopathological and molecular typing (ki-67 or PD-L1 expression, HER-2 status, K-RAS mutations, etc. ), prognostic and predictive value, treatment planning, response assessment, and follow up [63][64][65][66][67][68][69][70][71][72][73][74]. In this setting, quantitative tumor biomarkers based on DECT include iodine concentration, Zeff values, and HU values [36,37,[75][76][77][78].…”

Section: The Future Of Dect Imagingmentioning

confidence: 99%

What To Expect (and What Not) From Dual-energy CT Imaging Now and in the Future?

García-Figueiras

2024

Preprint

View full text Add to dashboard Cite

Dual-energy CT (DECT) imaging has broadened the potential of CT imaging by offering multiple postprocessing datasets with a single acquisition at more than one energy level. DECT shows profound capabilities to improve diagnosis based on its superior material differentiation and its quantitative value. However, the potential of dual energy imaging remains relatively untapped, possibly due to its intricate workflow and intrinsic technical limitations of DECT. Knowing the clinical advantages of dual-energy imaging and recognizing its limitations and pitfalls is neces-sary for an appropriate clinical use. The aims of this paper are to review physical and technical basis of DECT acquisition and analysis, to discuss advantages and limitations of DECT in dif-ferent clinical scenarios, to review technical constraints in material labeling and quantification, and to evaluate cutting-edge applications of DECT imaging, including artificial intelligence, qualitative and quantitative imaging biomarkers, and DECT-derived radiomics and radioge-nomics

show abstract

Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma

Cited by 8 publications

References 42 publications

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab

What To Expect (and What Not) From Dual-energy CT Imaging Now and in the Future?

Contact Info

Product

Resources

About